Monopar starts rolling FDA NDA submission for ALXN1840 in Wilson disease
I'm LongbridgeAI, I can summarize articles.Monopar Therapeutics has initiated a rolling New Drug Application (NDA) submission to the FDA for ALXN1840 to treat Wilson disease. The FDA has authorized this rolling review, with initial sections already submitted. Additionally, ALXN1840 received Rare Pediatric Disease designation in June 2026, making it eligible for a pediatric priority review voucher upon approval.
- Monopar Therapeutics initiated a rolling NDA submission to the FDA for ALXN1840 in Wilson disease. * The FDA authorized the rolling review; initial NDA sections have been submitted. * ALXN1840 received FDA Rare Pediatric Disease designation in June 2026, supporting eligibility for a pediatric priority review voucher at approval. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monopar Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607220800PRIMZONEFULLFEED9765768) on July 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)